AzTrials
AzTrials

Infection, Human Immunodeficiency VirusPhase 1NCT01754116

A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects

A Phase 1 study testing GSK1265744 30 mg oral, Midazolam 3 mg oral + GSK1265744 30mg oral and GSK1265744 400 mg (200 nm) in people with Infection, Human Immunodeficiency Virus, run by ViiV Healthcare at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a single-center, randomized, open-label, 3 parallel treatment study in healthy adult subjects to assess the relative bioavailability of new formulations of GSK1265744 LAP 400 mg intra muscular compared to the current GSK1265744 LAP 400 mg nanomilled formulation. Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Infection, Human Immunodeficiency Virus
What is being tested?
GSK1265744 30 mg oral, Midazolam 3 mg oral + GSK1265744 30mg oral and GSK1265744 400 mg (200 nm)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
43 participants
Where
1 siteUnited States
Study dates
Jan 2013to Apr 2014
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Male or female between 18 and 65 years of age inclusive, at the time of signing the informed consent.
  • Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.
  • A female subject is eligible to participate if she is of: non-childbearing potential. Female subjects of child bearing potential must agree to use contraception for at least 6 months after the final dose of study drug and should understand that drug concentrations may be measurable for up to one year after final dose.
  • Male subjects with female partners of child-bearing potential must agree to use one of the required contraception methods noted in the protocol.
  • Body weight >=50 Kilograms (kg) for men and >=45 kg for women and body mass index (BMI) within the range 18.5-31.0 kg/m^2 (inclusive).
  • Alanine aminotransferase (ALT), alkaline phosphatase and bilirubin <= 1.5xupper limit of normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
  • Single QTcB <450 msec.

Who cannot join

  • A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • A positive pre-study drug/alcohol screen.
  • A positive test for Human Immunodeficiency Virus (HIV) antibody.
  • History of regular alcohol consumption within 6 months of the study defined as:
  • An average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 grams (g) of alcohol: 12 ounces (360 milliliters [mL]) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.
Show all 22Show fewer
  • History or regular use of tobacco-or nicotine-containing products within 3 months prior to screening.
  • The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
  • Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
  • History of sensitivity to any of the study medications, including midazolam and flumazenil, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
  • History or presence of allergy or intolerance to the study drugs or their components or drugs of their class.
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
  • Pregnant females as determined by positive serum or urine hCG test at screening or prior to dosing.
  • Lactating females.
  • Unwillingness or inability to follow the procedures outlined in the protocol.
  • Subject is mentally or legally incapacitated.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia.
  • Unable to refrain from consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication.
  • The subject's systolic blood pressure is outside the range of 90-140mmHg, or diastolic blood pressure is outside the range of 45-90mmHg.
  • History of clinically significant cardiovascular disease.
  • Any significant arrhythmia which, in the opinion of the principal Investigator and GSK Medical Monitor, will interfere with the safety for the individual subject. Non-sustained (>=3 consecutive ventricular ectopic beats) or sustained ventricular tachycardia.

Trial locations and contacts

1 site in 1 country.

United States1 site

  • GSK Investigational Site

    Overland Park, Kansas, 66211

Other trials in United States

About this study

Official title: A Single-Center Randomized, Open-Label, Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 LAP in Healthy Adult Subjects.

This is a single-center, randomized, open-label, 3 parallel treatment study in healthy adult subjects to assess the relative bioavailability of new formulations of GSK1265744 LAP 400 mg intra muscular compared to the current GSK1265744 LAP 400 mg nanomilled formulation. This study will evaluate LAP formulations of GSK1265744 with different particle sizes.

Following a 14 day lead in period with oral GSK1265744, forty-five subjects will receive 400 mg of one of three GSK1265744 formulations which vary in particle size from 200 nm to 5 um by intramuscular injection. Samples for determination of GSK1265744 concentrations will be collected for 12 weeks post-injection. Safety will be evaluated by adverse event recording and laboratory values at frequent intervals throughout the trial. A subgroup of 12 subjects will receive a 3 mg dose of oral midazolam at baseline on Day-29 and then again on the last day of the oral GSK1265744 lead in period to evaluate the effect of GSK1265744 on CYP3A enzymes.

The subjects will undergo follow-up evaluations for a minimum of 12 weeks.

Being tested
GSK1265744 30 mg oral, Midazolam 3 mg oral + GSK1265744 30mg oral, GSK1265744 400 mg (200 nm), GSK1265744 400 mg (1 micro m), GSK1265744 400 mg (5 micro m)
Keywords
healthy subjects, GSK1265744 LAP, integrase inhibitor, HIV-1 infection, long acting retroviral, relative bioavailability
Medical subject headings
Infections, Acquired Immunodeficiency Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • GSK1265744 30 mg oralDrug

    GSK1265744B 30 mg Tablet taken orally, once a day in the morning with or without a meal

  • Midazolam 3 mg oral + GSK1265744 30mg oralDrug

    Midazolam Syrup 3mg each mL Oral/single dose administer by oral syringe on Day -29 and Day -14

  • GSK1265744 400 mg (200 nm)Drug

    A single dose of GSK1265744 400 mg Intra Muscular (IM) injection (Nanomilled 200 nm)

  • GSK1265744 400 mg (1 micro m)Drug

    A single dose of GSK1265744 400 mg IM injection (Nanomilled 1 micrometer)

  • GSK1265744 400 mg (5 micro m)Drug

    A single dose of GSK1265744 400 mg IM injection (Dry milling and homogenization 5 micrometer)

Study groups in NCT01754116
Study groupRoleWhat they receive
Lead In Period GSK1265744 30 mg + midazolam 3mgExperimentalDuring the lead-in period, a group of 12 subjects will receive a midazolam probe (on Day -29 and Day -14) to examine the potential of GSK265744 to inhibit or induce cytochrome P450 (CYP)3A activity. On Day -28, subjects will begin a 14 day oral dose of GSK265744 30 mg. to be taken once daily from Day-28 to Day -14. Subjects will begin a wash out period from Day -14 to Day -1 and be randomized to GSK1265744 LAP on Day 1
Receives: Drug: Midazolam 3 mg oral + GSK1265744 30mg oral
Lead in Period GSK1265744 30mgExperimentalOn Day -28, subjects will begin a 14 day oral dose lead-in period. Subjects will be dispensed a 14 day supply of 30mg oral GSK1265744 to be taken once daily from Day-28 to Day -15. Subjects will begin a wash out period from Day -14 to Day -1 and be randomized to GSK1265744 LAP on Day 1
Receives: Drug: GSK1265744 30 mg oral
Treatment AExperimentalApproximately 15 subjects will be enrolled and randomized on Day 1 to receive a single dose of 400 mg GSK1265744 (Nanomilled 200 nm) LAP intramuscular suspension injection
Receives: Drug: GSK1265744 400 mg (200 nm)
Treatment BExperimentalApproximately 15 subjects will be enrolled and randomized on Day 1 to receive a single dose of 400mg GSK1265744 (Nanomilled 1 micro m) LAP intramuscular suspension injection
Receives: Drug: GSK1265744 400 mg (1 micro m)
Treatment CExperimentalApproximately 15 subjects will be enrolled and randomized on Day 1 to receive a single dose of 400 mg GSK1265744 (Dry milling and homogenization 5 micro m) LAP intramuscular suspension injection
Receives: Drug: GSK1265744 400 mg (5 micro m)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Plasma GSK1265744 area under the concentration-time curve for 12 weeks (AUC 0-wk12)

    To evaluate the relative bioavailability of two new formulations of GSK1265744 400 mg LAP given intramuscularly compared to the current formulation (200 nm particle size) the pharmacokinetic (PK) parameters will include AUC 0 - 12

    Measured: Treatment Period: Day 1 pre-dose and 4 hour (h) post dose, 48 h (Day 3), 96 h (Day 5), 144 h (Day 7), Week 2, Week 3, Week 4, Week 6, Week 8, Week 12

  2. Plasma GSK1265744 last observed quantifiable concentration at week 12 (Cwk12)

    To evaluate the relative bioavailability of two new formulations of GSK1265744 400 mg LAP given intramuscularly compared to the current formulation (200 nm particle size) the PK parameters will include Cwk12

    Measured: Week 12

  3. Plasma GSK1265744 maximum observed concentration (Cmax)

    To evaluate the relative bioavailability of two new formulations of GSK1265744 400 mg LAP given intramuscularly compared to the current formulation (200 nm particle size) the PK parameters will include the maximum observed concentration

    Measured: Treatment period: Day 1 (pre-dose) and 4 hour (h) post dose, 48 h (Day 3), 96 h (Day 5), 144 h (Day 7), Week 2, Week 3, Week 4, Week 6, Week 8, Week 12, Week 14 (follow-up)

Secondary outcomes (22)

  1. Plasma GSK1265744 AUC(0-infinity) following the long acting parenteral (LAP) dosing

    Plasma GSK1265744 AUC(0-infinity), AUC(0-wk4), Cwk4, AUC(0-wk8), Cwk8, t½, tmax, and CL/F following the LAP dosing

    Measured: Day 1 (pre-dose) and 4 hour (h) post dose, 48 h (Day 3), 96 h (Day 5), 144 h (Day 7), Week 2, Week 3, Week 4, Week 6, Week 8, Week12 and Week 14 (follow-up)

  2. Plasma GSK1265744 AUC(0-wk4) and AUC(0-wk8) following the LAP dosing

    Plasma GSK1265744 AUC(0- infinity), AUC(0-wk4), Cwk4, AUC(0-wk8), Cwk8, t½, tmax, and CL/F following the LAP dosing

    Measured: Day 1 (pre-dose) and 4 hour (h) post dose, 48 h (Day 3), 96 h (Day 5), 144 h (Day 7), Week 2, Week 3, Week 4, Week 6, Week 8

  3. Plasma GSK1265744 Cwk4 and Cwk8 following the LAP dosing

    Plasma GSK1265744 AUC(0- infinity), AUC(0-wk4), Cwk4, AUC(0-wk8), Cwk8, t½, tmax, and CL/F following the LAP dosing

    Measured: Week 4 and Week 8

  4. Plasma GSK1265744 terminal phase half-life (t½) and time of occurrence of Cmax (tmax) following the LAP dosing

    Plasma GSK1265744 AUC(0- infinity), AUC(0-wk4), Cwk4, AUC(0-wk8), Cwk8, t½, tmax, and CL/F following the LAP dosing

    Measured: Day 1 (pre-dose) and 4 hour (h) post dose, 48 h (Day 3), 96 h (Day 5), 144 h (Day 7), Week 2, Week 3, Week 4, Week 6, Week 8, Week12 and Week 14 (Follow-up)

  5. Plasma GSK1265744 apparent clearance (CL/F) following oral dosing

    Plasma GSK1265744 AUC(0- infinity), AUC(0-wk4), Cwk4, AUC(0-wk8), Cwk8, t½, tmax, and CL/F following the LAP dosing

    Measured: Day 1 (pre-dose) and 4 hour (h) post dose, 48 h (Day 3), 96 h (Day 5), 144 h (Day 7), Week 2, Week 3, Week 4, Week 6, Week 8, Week12 and Week 14 (Follow-up)

  6. Plasma GSK1265744 AUC(0-wk12) and AUC(0-wk4) following LAP administration of 400 mg IM (unsplit) in Cohorts 3 and 8 of LAI114433 (historical control)

    Following LAP administration of 400 mg IM (unsplit) in Cohorts 3 and Cohort 8 of LAI114433 (ClinicalTrials.gov Identifier: NCT01215006) for historical control Route C material.the following PK parameters will be determined AUC(0-wk12) and AUC(0-wk4)

    Measured: Day 1 (pre-dose) and 4 hour (h) post dose, 48 h (Day 3), 96 h (Day 5), 144 h (Day 7), Week 2, Week 3, Week 4, Week 6, Week 8, Week 12

  7. Plasma GSK1265744 Cwk12 following LAP administration of 400 mg IM (unsplit) in Cohorts 3 and 8 of LAI114433 (historical control)

    Following LAP administration of 400 mg IM (unsplit) in Cohorts 3 and Cohort 8 of LAI114433 (ClinicalTrials.gov Identifier: NCT01215006) for historical control Route C material.the following PK parameter will be determined Cwk12

    Measured: Week 12

  8. Plasma GSK1265744 Cmax following LAP administration of 400 mg IM (unsplit) in Cohorts 3 and 8 of LAI114433 (historical control)

    Following LAP administration of 400 mg IM (unsplit) in Cohorts 3 and Cohort 8 of LAI114433 (ClinicalTrials.gov Identifier: NCT01215006) for historical control Route C material.the following PK parameter will be determined Cmax

    Measured: Day 1 (pre-dose) and 4 hour (h) post dose, 48 h (Day 3), 96 h (Day 5), 144 h (Day 7), Week 2, Week 3, Week 4, Week 6, Week 8, Week12 and Week 14 (Follow-up)

  9. Plasma GSK1265744 area under the concentration-time curve over the dosing interval (AUC(0-tau)) following oral administration of GSK1265744 with midazolam

    Following the LAP administration of the GSK 1265744 with midazolam the following PK parameter will be determined AUC(0-tau)

    Measured: During the oral lead in period: on Day -29, Day Day -28, Day -15, Day -14, Day -13

  10. Plasma GSK1265744 Cmax following oral administration of GSK1265744 with midazolam

    Following the LAP administration of the GSK 1265744 with midazolam the following PK parameter will be determined -Cmax

    Measured: During the oral lead in period: on Day -29, Day Day -28, Day -15, Day -14, Day -13

  11. Plasma GSK1265744 t½ and tmax following oral administration of GSK1265744 with midazolam

    Following the LAP administration of the GSK 1265744 with midazolam the following PK parameter will be determined t½ and tmax

    Measured: During the oral lead in period: on Day -29, Day Day -28, Day -15, Day -14, Day -13

  12. Plasma GSK1265744 CL/F following oral administration of GSK1265744 with midazolam

    Following the LAP administration of the GSK 1265744 with midazolam the following PK parameter will be determined CL/F

    Measured: During the oral lead in period: on Day -29, Day Day -28, Day -15, Day -14, Day -13

  13. Plasma AUC(0-infinity) and last time of quantifiable concentration within a subject across all treatments (AUC(0-t)) of midazolam following oral administration of midazolam alone and in combination with oral GSK1265744

    Following oral administration of midazolam alone and in combination with oral GSK1265744 the following PK parameters will be determined: AUC(0-infinity) and (AUC(0-t))

    Measured: During the oral lead in period: on Day -29, Day Day -28, Day -15, Day -14, Day -13

  14. Plasma Percentage of AUC(0-infinity) obtained by extrapolation (%AUCex )of midazolam following oral administration of midazolam alone and in combination with oral GSK1265744

    Following oral administration of midazolam alone and in combination with oral GSK1265744 the following PK parameters will be determined: %AUCex

    Measured: During the oral lead in period: on Day -29, Day Day -28, Day -15, Day -14, Day -13

  15. Plasma Cmax of midazolam following oral administration of midazolam alone and in combination with oral GSK1265744

    Following oral administration of midazolam alone and in combination with oral GSK1265744 the following PK parameters will be determined Cmax

    Measured: During the oral lead in period: on Day -29, Day Day -28, Day -15, Day -14, Day -13

  16. Plasma t1/2, tlag and tmax of midazolam following oral administration of midazolam alone and in combination with oral GSK1265744

    Following oral administration of midazolam alone and in combination with oral GSK1265744 the following PK parameters will be determined t1/2, Lag time before observation of drug concentrations in sampled matrix (tlag)and tmax

    Measured: During the oral lead in period: on Day -29, Day Day -28, Day -15, Day -14, Day -13

  17. Plasma CL/F of midazolam following oral administration of midazolam alone and in combination with oral GSK1265744

    Following oral administration of midazolam alone and in combination with oral GSK1265744 the following PK parameters will be determined CL/F

    Measured: During the oral lead in period: on Day -29, Day Day -28, Day -15, Day -14, Day -13

  18. Safety and tolerability assessed by the collection of all adverse events

    Following administration of the study treatment safety and tolerability which includes adverse events (AEs) will be assessed. AEs will be collected from the start of study treatment and until the follow-up contact

    Measured: Upto Week 14

  19. Safety and tolerability assessed by the collection of any use of concurrent medications

    Following administration of the study treatment safety and tolerability which includes concurrent medications taken by the subjects will be assessed

    Measured: Upto Week 14

  20. Safety and tolerability assessed by clinical laboratory screens

    Following administration of the study treatment safety and tolerability which includes clinical laboratory screens will be assessed. Hematology, clinical chemistry, urinalysis

    Measured: Day -1, Week 2, Week 4, Week 8, Week12 and Week 14 (Follow-up)

  21. Safety and tolerability assessed by electrocardiograph (ECG)

    Following administration of the study treatment safety and tolerability which includes ECG readings will be assessed. ECGs will be obtained at each timepoint during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTcB intervals

    Measured: Upto Week 14

  22. Safety and tolerability assessed by vital signs (blood pressure and pulse rate)

    Following administration of the study treatment safety and tolerability which includes vital signs will be assessed. Vital sign measurements will include systolic and diastolic blood pressure and pulse rate

    Measured: Upto Week 14

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Dec 2012 (estimated)
  2. Study startJan 2013
  3. Primary completionApr 2014
  4. Study completionApr 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
43 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01754116
Sponsor's protocol ID
116815
Status last verified
Apr 2014
First submitted
17 Dec 2012
Last updated
21 Apr 2014
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing GSK1265744 30 mg oral, Midazolam 3 mg oral + GSK1265744 30mg oral and GSK1265744 400 mg (200 nm) in people with Infection, Human Immunodeficiency Virus, run by ViiV Healthcare at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Apr 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Plasma GSK1265744 area under the concentration-time curve for 12 weeks (AUC 0-wk12) (time frame: Treatment Period: Day 1 pre-dose and 4 hour (h) post dose, 48 h (Day 3), 96 h (Day 5), 144 h (Day 7), Week 2, Week 3, Week 4, Week 6, Week 8, Week 12). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01754116.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Apr 2014.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in